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Abstract
Background A hip fracture is a debilitating condition that
consumes significant resources in the United States. Sur-
gical treatment of hip fractures can achieve better survival
and functional outcomes than nonoperative treatment, but
less is known about its economic benefits.
Questions/purposes We asked: (1) Are the societal ben-
efits of hip fracture surgery enough to offset the direct
medical costs? (2) Nationally, what are the total lifetime
benefits of hip fracture surgery for a cohort of patients and
to whom do these benefits accrue?
Methods We estimated the effects of surgical treatment
for displaced hip fractures through a Markov cohort
analysis of patients 65 years and older. Assumptions
were obtained from a systematic literature review, ana-
lysis of Medicare claims data, and clinical experts. We
conducted a series sensitivity analyses to assess the effect
of uncertainty in model parameters on our estimates. We
compared costs for medical care, home modification, and
long-term nursing home use for surgical and nonopera-
tive treatment of hip fractures to estimate total societal
savings.
Results Estimated average lifetime societal benefits per
patient exceeded the direct medical costs of hip fracture
surgery by USD 65,000 to USD 68,000 for displaced hip
fractures. With the exception of the assumption of nursing
home use, the sensitivity analyses show that surgery pro-
duces positive net societal savings with significant
deviations of 50% from the base model assumptions. For
an 80-year-old patient, the breakeven point for the
assumption on the percent of patients with hip fractures
who would require long-term nursing home use with
nonoperative treatment is 37% to 39%, compared with 24%
for surgical patients. Nationally, we estimate that hip
fracture surgery for the cohort of patients in 2009 yields
lifetime societal savings of USD 16 billion in our base
model, with benefits and direct costs of USD 21 billion and
USD 5 billion, respectively. For an 80-year-old, societal
benefits ranged from USD 2 billion to USD 32 billion,
using our range of estimates for nursing home use among
nonoperatively treated patients who are immobile after the
fracture.
Conclusions Surgical treatment of hip fractures produces
societal savings. Although the magnitude of these savings
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depends on model assumptions, the finding of societal
savings is robust to a range of parameter values.
Level of Evidence Level III, economic and decision
analyses. See the Instructions for Authors for a complete
description of levels of evidence.
Introduction
More than 300,000 patients sustain a hip fracture each year
in the United States [3]. These serious injuries often result
in nursing home stays, increased mortality, and overall
lower quality of life [5, 13, 20, 24, 25, 41]. Hip fracture
rates increase exponentially with age [34], with approxi-
mately 90% of hip fractures occurring in people older than
65 years [36]. As the US population ages, the incidence of
hip fracture is expected to increase substantially. One study
estimated that by 2040, the annual incidence of hip frac-
tures will exceed 500,000 in the United States population
[32]. These continuing trends will place a financial burden
on patients, families, insurers, and governments.
Although surgery is the predominant treatment strategy
for hip fractures because it reduces mortality risk and
improves physical functioning for many patients, less is
known about its societal cost implications. With policy
makers and payers increasingly focused on value, it is
critical to understand the return from healthcare spending.
In this study, we considered the economic returns from
spending on hip fracture. The broader economic effects of
surgical treatment for hip fractures are reflected in direct
medical costs and indirect costs, including long-term
medical costs, custodian costs associated with nursing
home stays, and the cost of home modification. Estimates
of the societal benefits of medical treatment help establish
a larger context for critically viewing overall healthcare
spending, which informs health policy decision making and
healthcare resource allocation.
We evaluated the economic value of surgical treatment
of hip fractures for patients who undergo surgery and
society in general by addressing two questions: (1) Are the
societal benefits of hip fracture surgery enough to offset the
direct medical costs? (2) Nationally, what are the total
lifetime benefits of hip fracture surgery for a cohort of
patients and to whom do these benefits accrue?
Materials and Methods
We estimated the effects of surgical treatment for displaced
intracapsular and extracapsular hip fractures through a
Markov cohort analysis (Fig. 1). The analysis was limited
to patients 65 years and older and results were generated
for cohorts ranging in age from 65 to 98 years and sum-
marized using the age distribution of patients with hip
fractures who undergo surgery in the United States. Model
assumptions (Table 1) were obtained from a systematic
literature review, analysis of Medicare claims data, and
clinical experts. We recruited and consulted a team of
experts with clinical experience in surgical and postoper-
ative care of patients with hip fractures. The expert panel
consisted of three orthopaedic surgeons (JOA, RFK,
DWL), two physical therapists (HR, JB), and one physical
medicine and rehabilitation physician (AK). For assump-
tions not available in the literature (assumptions related to
nonoperative treatment), we relied on the consensus
reached by the clinical experts through a series of inter-
views and questionnaires.
We ran separate models for each of four surgical tech-
niques: hemiarthroplasty and THA for displaced
intracapsular fractures and intramedullary and extramedul-
lary implants for extracapsular fractures. Internal fixation
was not modeled for displaced intracapsular hip fractures
since it is not the preferred treatment for older patients [16].
To assess the effect of uncertainty in model assumptions, we
conducted a series of sensitivity analyses that tested a rea-
sonable range of all parameters in the Markov model for a
representative 80-year-old (Table 2). These sensitivity
analyses show the effect of changes in each model parameter
(eg, first year mortality rate) on model outputs. We also
performed scenario sensitivity analyses in which multiple
parameters changed simultaneously to test model outputs
under more extreme conditions. The model was estimated in
TreeAge Pro 2011 (TreeAge Software, Inc, Williamstown,
Fig. 1A–B (A) A decision tree shows the treatment pathway and
health states in the Markov model of hip fractures. The surgical
branch of intracapsular fractures consists of four health states: dead,
well, infection revision, and aseptic revision (infection and aseptic
revisions are represented by one oval in the figure). In the first year
after surgery, living patients enter the well state. The well state
includes good and fair outcomes. For patients in the well state, they
can die, stay in that health state, or have a revision surgery in the
subsequent year. The nonoperative branch consists of three states:
dead, survive - immobile, and survive - mobile. Once patients enter
either survive - immobile or survive - mobile, they stay there until
they die. (B) The surgical branch of extracapsular fractures consists of
five health states: dead, well, conversion to arthroplasty, infection
revision arthroplasty, and aseptic revision arthroplasty (infection and
aseptic revisions are represented by one oval in the figure). The well
state includes good and fair outcomes, because distribution and utility
data for these separate health states were unavailable for extracapsular
fracture. Patients can die, do well, or undergo conversion surgery to
arthroplasty during the first year. For patients who had a conversion to
arthroplasty, they can die, stay in that state, or have a revision
arthroplasty in the subsequent year. The nonoperative branch consists
of three states: dead, survive - immobile, and survive - mobile. Once
patients enter either survive - immobile or survive - mobile, they stay
there until they die.
c
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MA, USA) using the Markov model transition probability
matrix. Additional details on the derivation of model
assumptions and approach are provided (Appendix 1. Sup-
plemental materials are available with the online version of
CORR1). Specifically, Appendix 1 includes additional
information regarding the use of the clinical experts, the
derivation of all-payer payments, and the development of
assumptions regarding long-term nursing home use.
3538 Gu et al. Clinical Orthopaedics and Related Research1
123
Table 1. Clinical parameters and utilities in base Markov model
Clinical parameters/
utilities
Displaced intracapsular fractures Extracapsular fractures


























































0.0193 [9] 0.0193 [9] NA 0.0193 [9] 0.0193 [9] NA
Probability of
mobility if survive
NA NA 0.5 [12] NA NA 0.5 [12]
Utility
Dead 0 0 0 0 0 0
Well 0.66 [22] 0.7 [22] NA 0.54 [10, 27] 0.54 [10, 27] NA
Conversion to
arthroplasty








0.39 [38, E] 0.39 [38, E] NA 0.38 [10, E] 0.38 [10, E] NA
Survive - mobile NA NA 0.39 [E] NA NA 0.38 [10, E]
Survive - immobile NA NA 0 [2] NA NA 0 [2]
Disutility - internal
fixation
0.15 [35] 0.15 [35] NA
Disutility - initial
arthroplasty
0.15 [35] 0.15 [35] NA 0.15 [35] 0.15 [35] NA
Disutility - revision
arthroplasty
0.2 [35] 0.2 [35] NA 0.2 [35] 0.2 [35] NA
Numbers in brackets indicate the source of information (ie, reference number of studies cited); E = expert opinion; NA = results not affected by
parameter.
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Clinical Parameters
Mortality rates after hip fracture vary [11, 20, 22, 29, 33,
39, 40]; we assumed overall relative risks of 3.07 and 1.87
during the first and second years after a hip fracture, with a
subsequent return to age-specific levels [13]. These values
then were applied to the age-specific natural mortality in
the US life tables [4]. For revision, we used the surgical
mortality rate of infection revision (1.2%) and aseptic
revision (1.9%) reported by Chang et al. [9] for hemiar-
throplasty and THA.
Few studies report mortality rates for nonoperative
treatment of hip fractures [14, 18, 19, 28]. We used the
existing literature to set the mortality rate equal to 1.33
times the mortality rate of patients treated surgically [18].
After the second year, we used the age-specific natural
mortality level for surgical and nonsurgical groups.
The long-term revision rate reported by Ravikumar and
Marsh [31] was used to estimate the rates for septic and
aseptic revision for intracapsular fracture.
For revision of extracapsular fracture treatment, we used
first-year revision rates as reported by Adam et al. [1], of
4% and 6% for patients treated with sliding hip screws and
intramedullary nails, respectively. We assumed that all
patients who needed a reoperation to treat failed internal
fixation received a conversion to THA within the first year.
For revision rates in subsequent years, we used the intra-
capsular revision rate that reflects revisions after THA. For
both types of hip fractures, we allowed no more than one
revision arthroplasty.
The utility values for the health states represented in
the model were attained from a review of the literature.
The utility values are used to estimate the Quality-
Adjusted Life Years (QALYs), which is a standard
metric to measure patient quality of life. QALY is the
product of the number of additional years to live as a
result of a treatment and the utility of the patient health
status in those years, with utility usually ranging from 0
for death to 1 for perfect health. For example, if a
treatment extends a patient’s life by 2 years and the
utility of patient health status after treatment is 0.8, we
would say that treatment leads to an additional 1.6 (ie,
2*0.8) QALYs. For the intracapsular and extracapsular
models, we used a one-time disutility of 0.15 for
arthroplasty and internal fixation and 0.2 for revision
arthroplasty [35].
Based on the available literature, we assumed that 50%
of the patients who are treated nonoperatively for displaced
intracapsular and extracapsular fractures can walk at the
conclusion of treatment. For both types of fractures, we set
a utility level of 0 for survivors of nonsurgical treatment
who cannot walk, based on our estimate using the US
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after treatment, their utility was set to be the same as the
utility after infection revision based on expert opinion.
Nursing Home Utilization
We developed estimates of the probability of being in a
nursing home before and after a hip fracture using findings
from the literature [6, 37], the 2004 National Nursing Home
Survey [21], and clinical expert input. The following
assumptions were made regarding nursing home use for
patients with hip fractures: (1) rates of long-term nursing
home use for patients treated surgically and for patients who
obtain mobility after nonsurgical treatment of a hip fracture
are 16% for patients 65 to 74 years old, 24% for patients 75
to 84 years old, and 48% for patients older than 85 years; and
(2) rates of long-term nursing home use for patients treated
nonsurgically and immobile are 53% for patients 65 to
74 years old, 57% for patients 75 to 84 years old, and 69%
for patients older than 85 years (Appendix 1. Supplemental
material is available with the online version of CORR1).
Cost Estimates
Estimates of the direct medical costs (which include
inpatient, postacute care, rehabilitation, outpatient, and
physician services, but exclude long-term nursing home
costs) associated with surgical and nonsurgical treatment
(Table 3) were derived from a payer perspective and based
on claims for a 5% sample of Medicare beneficiaries in
2009 but adjusted to reflect all payer costs. We accumu-
lated medical costs incurred from hospitalization for hip
fracture to 6 months after the hospital discharge from
Medicare claims. Long-term (ie, beyond 6 months) annual
medical costs are likely to be higher in the nonoperative
group than in the surgical group because of increased
functional limitations [14]. Based on literature [7, 8, 14]
and expert opinion, we assumed long-term annual health-
care costs of USD 12,941 for surgically treated patients and
USD 14,790 for nonoperatively treated patients. We
assumed an annual nursing home cost of USD 74,498
(2009 USD) based on the 2011 MetLife Market Survey of
Nursing Homes [26] and a one-time home modification
cost of USD 349 based on our estimates using the 2010
Health and Retirement Study [15].
Results
Are the societal benefits of hip fracture surgery enough to
offset the direct medical costs? We estimated that the
lifetime benefits to society from surgical treatment of hip
fracture more than offset the direct medical costs, with
average savings per patient of USD 65,279 and USD
67,964 for displaced intracapsular and extracapsular hip
fractures, respectively (Table 4). For displaced intracap-
sular fractures, the surgical treatment cost USD 19,710
more than nonoperative treatment, which was offset by
savings of USD 84,990 from lower long-term medical costs
and reduced nursing home use. For extracapsular fractures,
the direct medical costs for surgical treatment were USD
22,317 higher than that of nonoperative treatment but were
offset by savings of USD 90,281. We estimated that the
surgical treatment of hip fractures produced an average
increase of 2.5 quality-adjusted life years (QALYs) for
patients with intracapsular fractures and 1.9 QALYs for
patients with extracapsular fracture (Table 4). Surgical
treatment was a dominant treatment strategy for hip frac-
ture when total societal savings were considered because it
achieved better quality of life at lower cost.
For both types of hip fractures, total societal savings and
increased QALYs from surgical treatments varied consid-
erably across age groups (Table 4). For example, surgical
treatment for an intracapsular fracture achieved approxi-
mately USD 160,000 in societal savings and 4.2 QALYs per
patient for patients 70 to 79 years old. For patients older
than 90 years, surgical treatment was more expensive
although still cost-effective.
Because avoided nursing home costs accounted for
most of the savings, the results were most sensitive to
Table 3. Average direct medical costs for 6 months after hip
fractures




Intracapsular Nonsurgical treatment 40,795
Extracapsular Internal fixation 54,054
Extracapsular Nonsurgical treatment 34,509
Both Revision hip arthroplasty 44,784
We analyzed 5% sample of 2009 Medicare inpatient claims; ICD-9
diagnosis codes 820.0x and 820.1x were used to identify patients with
intracapsular fractures and 820.2x and 820.3x for extracapsular
fractures. The following ICD-9 procedure codes were used to identify
relevant procedures: 81.51 (THA), 81.52 (hemiarthroplasty), 79.35
(open reduction and internal fixation), 81.53 and 00.70 to 00.73
(revision hip arthroplasty); *cost estimates were risk-standardized for
age, sex, and comorbidities and adjusted to reflect different reim-
bursement rates across payers (eg, private, Medicare, Medicaid, self-
insured, and uninsured); estimates include all medical costs (facility
and physician fees) across all care settings (including readmissions to
hospital, outpatient, and postacute care facilities) from the index
hospitalization to 6 months after discharge from the index hospital-
ization; all costs are expressed in 2009 USD.
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changes in the parameters related to nursing home use.
For an 80-year-old, the breakeven point for the assump-
tion on the percent of patients with hip fractures who
would require long-term nursing home use with nonop-
erative treatment is 37% to 39%, as compared with 24%
for surgical patients. That is, avoided nursing home costs
would offset the increased cost of surgery for hip fracture
when the probability of requiring nursing home use is
13% to 15% higher with nonoperative treatment than with
surgical treatment. For all other parameters, the sensitiv-
ity analysis showed that surgery always produced a
positive net societal savings even with significant devia-
tions (eg, 50%) from the base model assumptions
(Table 2). We also performed scenario sensitivity analy-
ses by changing multiple parameters simultaneously to
test the robustness of our estimates under more extreme
scenarios (Appendix 1. Supplemental materials are
available with the online version of CORR1). Overall,
our saving estimates were relatively robust to parameter
assumptions. The QALY estimates were relatively sensi-
tive to the utility of being well after surgery to treat
extracapsular fractures.
Nationally, what are the total lifetime benefits of hip
fracture surgery for a cohort of patients and to whom do
these benefits accrue? At the national level, our findings
suggested societal savings from surgical treatment of hip
fractures of USD 16 billion for elderly patients in 2009
(based on 307,538 hospital discharges in the United States
[3], 90% occurring in patients 65 years or older [36], 1
.
2
being extracapsular fractures [12], and 85% of intracap-
sular fractures displaced [30]). The lifetime total societal
benefits from surgical treatment of hip fractures were
approximately USD 21 billion with direct medical costs of
USD 5 billion. Almost all the benefits ([ 95%) were from
avoided nursing home costs, which largely accrued to state
Medicaid programs and patients. The remaining benefits
came from lower long-term medical spending, which lar-
gely accrued to government payers (Medicare and
Medicaid). As with our individual-level estimates, the
national savings estimates are sensitive to the assumption
of nursing home use under the nonoperative treatment
scenario. Using the range of assumptions for rate of long-
term nursing home use among immobile patients after
nonsurgical treatment (Table 2), we estimate that societal
benefits at the national level range from USD 2 billion to
USD 32 billion, with societal savings ranging from USD
3 billion (USD 2 billion to 5 billion) to USD 27 billion
(USD 32 billion to 5 billion). Thus, in our most
Table 4. Societal savings and additional QALYs from surgical treatment of hip fractures
Age
group


















28,006 18,811 312,781 129 303,458 6.1 Dominant
70–79
years
23,941 8993 176,688 120 161,620 4.2 Dominant
80–89
years
18,914 705 49,635 93 29,923 2.2 Dominant
90+
years
14,896 3336 5905 73 12,400 0.8 19,544




22,447 21,451 318,329 129 317,203 4.6 Dominant
70–79
years
22,380 10,901 181,982 120 170,383 3.1 Dominant
80–89
years
22,305 378 53,922 93 31,902 1.6 Dominant
90+ 22,244 2892 7675 73 17,533 0.6 37,073
Overall 22,317 3190 87,188 97 67,964 1.9 Dominant
Values are estimated relative to nonsurgical treatments; Column E is calculated as the sum of columns A through D; negative values in E
(negative savings) represent increases in societal costs; savings by age groups were weighted by age distribution of the patient population to
reach overall savings; all savings are expressed in 2009 USD; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio,
calculated using differences in total costs.
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conservative estimate, surgical treatment of hip fracture
yields reduced nursing home costs that offset almost 40%
of the additional cost of surgery (0.4 = 2 billion/5 billion).
Discussion
Surgical treatment is considered standard of care for the
majority of patients with hip fractures, but evidence
regarding the value of surgical treatment of these fractures
from a societal perspective is missing in the current liter-
ature. In this study, we used a Markov model to assess cost
and benefit from operative treatment. We sought to deter-
mine whether: (1) the societal benefits of hip fracture
surgery are enough to offset the direct medical costs, and
(2) the total lifetime benefits of hip fracture surgery for a
cohort of patients and to whom these benefits accrue.
The primary limitations of the study occur because of a
lack of high-quality data regarding outcomes for nonsur-
gical treatment of hip fractures. The assumption regarding
nursing home use among immobile patients (ie, 90%) is
especially important since most of the societal savings
were from avoidance of prolonged use of nursing homes.
To develop assumptions regarding outcomes under the
nonoperative treatment scenario, we relied on a small
number of studies and expert opinion. We similarly
developed assumptions regarding number of activities of
daily living for patients with hip fractures who do not
receive surgery and then relied on literature associating
healthcare spending with number of activities of daily
living. To address the potential effects of bias on the study
conclusions from gaps in the data, we conducted extensive
sensitivity analyses, which revealed savings even under
assumptions more favorable to nonsurgical treatment.
There are two additional potential limitations. First,
patients undergoing surgery may be healthier at the outset
than patients who are treated nonoperatively; thus, differ-
ence in outcomes observed in the literature could be
influenced by treatment selection. Second, since the 5%
Medicare dataset we used to estimate costs includes few
patients younger than 65 years, we cannot necessarily
extrapolate the results here to younger patients.
We estimated age-weighted, lifetime savings to society
for surgical treatment of hip fractures to be more than USD
65,000 per patient, with surgical treatment of hip fractures
producing 2.5 and 1.9 additional QALYs compared with
nonsurgical treatment for displaced intracapsular and
extracapsular hip fractures, respectively. Almost all of the
societal savings from surgical treatment of hip fracture
were from avoided nursing home costs. Although there are
no comparable studies in the literature showing the value of
surgical treatment for hip fractures, studies have docu-
mented the high personal and financial cost of hip fracture.
Braithwaite et al. [6] estimated that a hip fracture reduces
life expectancy by 1.8 years with the lifetime cost of a hip
fracture at USD 81,300 (1997 dollars). Approximately 44%
of these costs were associated with nursing facility
expenses. Other studies have documented substantial
reductions in functional status with hip fractures [5, 6, 10,
12, 17, 24, 41]. Consistent with our findings of savings
from surgical treatment, studies of nonoperative treatment
for hip fractures, while limited, report high rates of
immobility (45%) [12] and dependency (29% of surgically
treated patients versus 57% nonoperatively treated) [18].
At the national level, our findings suggested substantial
societal savings from surgical treatment of hip fractures.
We estimated that the lifetime total societal savings from
surgical treatment of hip fractures was USD 16 billion for
elderly patients treated in 2009, mainly from avoidance of
nursing home costs. By comparison, Braithwaite et al. [6]
estimated lifetime cost for all hip fractures in the US of at
least USD 20 billion. Thus, while hip fractures impose
substantial societal costs, the results show that surgery has
an important role in minimizing the societal burden of hip
fractures.
Our study is the first to our knowledge to quantify the
economic value of surgical treatment of hip fractures in
terms of reduced lifetime societal costs. The scope of
factors considered for the calculation of value extended
beyond direct medical treatment costs to the long-term
medical costs associated with impaired functioning and to
nursing home costs accumulated during a lifetime.
Although the magnitude of the societal savings depends on
model assumptions, the finding of societal savings is robust
to a range of parameter values. Because the study focused
on the cohort of patients receiving surgery, our results
should not be interpreted as suggesting that surgery is
appropriate for all patients with hip fractures. This analysis,
however, serves as an important benchmark for the eco-
nomic value of surgery for hip fractures. The method used
in our study can be used in future studies to show the
additional economic effects as hip fracture care is
improved. Future studies also might consider that addi-
tional benefits to society from improved employment and
productivity resulted from successful surgical treatment of
hip fractures, as more elderly workers choose to stay in the
labor force longer [23].
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